Iranian
Biomedical Journal
Volume 10, Issue 3 (7-2006)
IBJ 2006, 10(3): 151-155 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nikvsarkar M, Banerjee A, Shah D, Trivedi J, Patel M, Cherian B et al . Reduction in Aluminum Induced Oxidative Stress by Meloxicam in Rat Brain. IBJ 2006; 10 (3) :151-155
URL: http://ibj.pasteur.ac.ir/article-1-370-en.html
URL: http://ibj.pasteur.ac.ir/article-1-370-en.html
Manish Nikvsarkar 
, Aryamitra Banerjee , Deval Shah , Jaimic Trivedi , Manoj Patel , Bapu Cherian , Harish Padh
, Aryamitra Banerjee , Deval Shah , Jaimic Trivedi , Manoj Patel , Bapu Cherian , Harish Padh
Abstract:
Background: Non-steroidal anti-inflammatory drugs (NSAID) have been associated with antioxidant property and have been shown to improve the circulating antioxidant status on daily dosing in different inflammatory conditions. The present study was conducted to investigate the antioxidant role of meloxicam in aluminum induced oxidative stress in rat brain. Methods: In the in vivo experiments, Sprague-Dawley rats where randomized into 4 groups receiving daily treatment for 4 weeks: 1) double distilled water i.p., 2) 4.2 mg/kg aluminum i.p. 3) meloxicam (5.0 mg/kg, i.m.) 4) 5.0 mg/kg, meloxicam i.m. + 4.2 mg/kg aluminum i.p. brain homogenates from the above animals were assayed for lipid peroxidation levels as well as superoxide dismutase activity. In the in vitro experiments, brain homogenates from Sprague-Dawley rats were treated with either, aluminum, meloxicam or their combinations and were then assayed as per the in vivo samples. Results: In vivo data showed elevated lipid peroxidation levels in brain homogenate in aluminium-treated group as compared to aluminium + meloxicam treatment which showed a significant decrease in the malonaldehyde levels. Similar results were observed in the in vitro experiments when brain homogenates were treated with either, aluminum, meloxicam or their combinations. Furthermore, no change was observed in superoxide dismutase activity in any treatment group as compared to the control in either experiment. Conclusion: These results indicate that NSAID can be used in Alzheimer management. Iran. Biomed. J. 10 (3): 151-155, 2006
Keywords: Superoxide dismutase (SOD), Lipid peroxidation (LPO), Meloxicam, Alzheimer’s disease, Aluminium
Type of Study: Full Length/Original Article |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |